PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
730.06%
Net income growth above 1.5x VET's 26.41%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-1.13%
Negative yoy D&A while VET is 9.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-34.93%
Negative yoy deferred tax while VET stands at 73.99%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
No Data
No Data available this quarter, please select a different quarter.
-202.47%
Negative yoy working capital usage while VET is 75.37%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-202.47%
Negative yoy usage while VET is 75.37%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-226.23%
Negative yoy while VET is 94.24%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-54.38%
Negative yoy CFO while VET is 57.02%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
3.94%
Some CapEx rise while VET is negative at -165.69%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
2126.86%
Growth well above VET's 942.30%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
145.10%
Investing outflow well above VET's 89.42%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-1910.91%
We cut debt repayment yoy while VET is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-17.39%
Both yoy lines negative, with VET at -23.63%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
-19.21%
We cut yoy buybacks while VET is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.